Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER?) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors

Tumor Biology

Volumn 32, Issue 4, 2011, Pages 745-751

  Galoian, Karina A ^a   Temple, Thomas H ^a   Galoyan, Armen ^b  

^a UNIVERSITY OF MIAMI HEALTH SYSTEM   (United States)

^b H Buniatian Institute of Biochemistry National Academy of Sciences of Armenia   (Armenia)

Author keywords

Breast carcinoma MDA 231 cell lines; c Myc; Cell cycle; Cytostatic effect; Hypothalamus; mTOR; Primary cultures; Proline rich polypeptide 1

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROLINE RICH POLYPEPTIDE 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL AGING; CELL CYCLE S PHASE; CELL DIVISION; CELL STRAIN MDA 231; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; ENZYME ACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; MESENCHYMOMA; MICROSCOPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIDEOMICROSCOPY;

EID: 80052338773     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0176-3     Document Type: Article

References (44)

1. Galoyan AA. Brain neurosecretory cytokines: immune response and neuronal survival. NY: Kluwer Academic/Plenum Publishers; 2004.
2. Galoyan A. The brain immune system: chemistry and biology of the signal molecules. In: Abel L, editor. Handbook of neurochemistry and neurobiology. NY: Springer; 2008. p. 155-96.
3. Galoyan AA, Grigorian SL, Badalyan CV. Treatment and prophylaxis of anthrax by brain neurosecretory cytokines. Neurochem Res. 2006;31(6):795-803. (Pubitemid 44114813)
4. Galoyan AA, Sarkissian JS, Chavushyan VA, et al. Neuroprotective action of hypothalamic peptide PRP-1 at various time survival following spinal cord hemisection. Neurochem Res. 2005;30(4):507-25. (Pubitemid 40933659)
5. Galoyan AA. Neurochemistry of brain neuroendocrine immune system: signal molecules. Neurochem Res. 2000;25(9/10):1343-55.
6. Galoyan AA, Aprikyan VS. A new hypothalamic polypeptide is a regulator of myelopoiesis. Neurochem Res. 2002;27(4):305-12. (Pubitemid 34273572)
7. Galoyan AA, Shakhlamov VA, Kondakova LI, Altukhova VI, Polyakova GP. The influence of proline-rich polypeptide on the morphology and mitotic activity of neurinoma Hassel node of tumor cells at rats (electron microscopic investigations). PNAS (Russian Academy of Sciences). 2001;101(2):279-86.
8. Galoyan AA, Shakhlamov VA, Malaytsev VV. Changes in tumor cells L929 under PRP effect in vitro. Med Sci Armenia. 2001;41 (1):25-9.
9. Galoyan AA, Margaryan KS, Hovhannisyan GG, Gasparyan GH, Aroutiounian DN, Aroutiounian RM. Study of the genotoxic effects of a proline-richpolypeptide using the comet assay. Neurochem Journal. 2009;3(2):145-8.
10. Aroutiounian RM, Hovhannisyan GG, Gasparyan GH, Margaryan KS, Aroutiounian DN, Aroutiounian DN, et al. Proline-rich polypeptide-1 protects the cells in vitro from genotoxic effects of mitomycin C. Neurochem Res Apr. 2010;35(4):598-602.
11. Chailakhyan RK, Gerasimov YV, Chailakhyan MR, Galoyan AA. Proline- rich hypothalamic polypeptide has opposite effects on the proliferation of human normal bone marrow stromal cells and human giant-cell tumour stromal cells. Neurochem Res. 2010;35 (6):934-9.
12. Galoian K, Scully S, McNamara G, Flynn P, Galoyan A. Antitumorigenic effect of brain proline rich polypeptide-1 in human chondrosarcoma. Neurochem Res. 2009;34(Issue 12):2117-21.
13. Galoian K, Scully S, Galoyan A. Myc-oncogene inactivating effect by proline rich polypeptide (PRP-1) in chondrosarcoma JJ012 cells. Neurochem Res. 2009;34(2):379-85.
14. Kaelin Jr WG, Craig B. Thompson clues from cell metabolism. Nature. 2010;465(3):562-4.
15. Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol. 1998;54(5):815-24. (Pubitemid 28523173)
16. Robert PC, Shiu PW, Dubik D. cMyc oncogene expression in estrogen dependent and independent breast cancer. Clin Chem. 1993;39(2):353-5. (Pubitemid 23069701)
17. Dubik D, Shiu RP. Mechanism of estrogen activation of cMyc oncogene expression. Oncogene. 1992;7:1587-94.
18. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992;52:1107-13.
19. Collins S, Groudine M. Amplification of endogenous myc- related DNA sequences in a human myeloid leukemic cell line. Nature. 1982;298:679-81. (Pubitemid 12099731)
20. Galoian K, Milne T, Brock H, Shilatifard A, Slany R, Hess JL. Deregulation of c-myc by leukemogenic MLL fusion proteins. Blood Acad Sci USA. 2000;90:8392-6. Suppl. 96, 457a.
21. Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D, et al. Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell Sep. 2003;4(3):197-207. (Pubitemid 37163834)
22. Ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G, Croce CM. Differential expression of the translocated and the untranslocated cmyc oncogene in Burkitt Lymphoma. Science. 1983;222:390-3. (Pubitemid 13012679)
23. Little CD, Nau MN, Carney DN, Gazdar AF, Minna JD. Small cell carcinoma of the lung: amplification and expression of the cmyc oncogene in human lung cancer cell lines. Nature. 1984;306:194-6.
24. Galoian KA, Temple HT, Galoyan AA. Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by its inhibition of mTOR and c-Myc in high grade metastatic chondrosarcoma. Neurochemical Res. 2011;36:812-8.
25. Barrios C, Castresana JS, Kreicbergs A. Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification. Am J Clin Oncol. 1994;17:273-6. (Pubitemid 24160623)
26. Chen Y, Olopade OI. MYC in breast tumor progression. Expert Rev Anticancer Ther. 2008;8:1689-98.
27. Hynes NE, Stoelzle T. Breast Cancer Research Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Research. 2009;11:210.
28. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia. 2007;9:443-54. (Pubitemid 46799988)
29. Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, et al. Meta-analysis and gene set enrichment relative to ER status reveal elevate activity of MYC and E2F in the 'basal' breast cancer subgroup. PLoS ONE. 2009;4: e4710.
30. Funasaka T, Hu H, Hogan V, Raz A. Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence. J Biol Chem. 2007;282(50):36362-9.
31. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436 (7051):725-30. (Pubitemid 41117277)
32. Harper JV (2005) Synchronization of cell populations in G1/S and G2/M phases of the cell cycle. In: T. Humphrey and G. Brooks. Methods in Molecular Biology, vol 296, Cell Cycle control, pp 157-166
33. Figlin RA et al. NCCN Task Force Report: mTOR inhibition in solid tumors. JNCCN. 2008;6(5):S1-S25.
34. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001;19(1):265-72. (Pubitemid 32063505)
35. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno- Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68 (4):987-97.
36. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;2(127):679-95. (Pubitemid 44781029)
37. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24 breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8:R59.
38. Hugo H, Ackland ML, Blick T, et al. Epithelial mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374-83. (Pubitemid 47509716)
39. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131-42. (Pubitemid 43278296)
40. Thiery JP. Epithelial -mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-54.
41. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 2005;65:5991-5. discussion 5. (Pubitemid 40994377)
42. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001;23:912-23. (Pubitemid 32972691)
43. Stingl J, Caldas. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7:791-9.
44. Laurenti E, Wilson A, Trumpp A. Mycs other life:stem cells and beyond. Curr Opin Cell Biol. 2009;21:844-54.